Navigation Links
Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
Date:3/14/2009

Med Discovery SA, a specialized protein-based therapeutics oncology company, is proud to announce that they have extended their global partnership agreement with Laborium Biopharma, a subsidiary of Validapro BioSciences Inc. to encompass the cell culture process development and clinical manufacturing of all molecules under development at Med Discovery.

(PRWEB) March 14, 2009 -- Med Discovery SA, a specialized protein-based therapeutics oncology company, is proud to announce that they have extended their global partnership agreement with Laborium Biopharma, a subsidiary of Validapro BioSciences Inc. to encompass the cell culture process development and clinical manufacturing of all molecules under development at Med Discovery.

This strategic decision will allow Med Discovery SA to have priority access to Laborium Biopharma's clinical manufacturing capabilities and all related specialized services to ensure compliance of all its development projects to international regulations.

Dr. Deperthes President and CEO at Med Discovery S.A said: "In the upcoming months, Med Discovery will start the manufacturing of new biologics produced in mammalian cells. With this new extended agreement Med Discovery SA will accelerate the development of these innovative products allowing faster entry into pre-clinical and clinical phases. Validapro BioSciences Inc. will bring the operational flexibility and process development expertise to design value-added programs to meet Global cGMP expectations".

Luc Dubois President of Laborium Biopharma added: "In this difficult worldwide financial situation, such partnership agreement opens a new way to do business by sharing respective core competencies to reduce the risk associated with product development. That shall benefit both companies. Validapro BioSciences Inc. will be acting as the process development and clinical manufac
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

3

GOOD

Page: 1 2

Related biology technology :

1. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
2. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
3. European Centre for Modern Drug Discovery Established in Hamburg
4. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
5. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
6. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
7. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
8. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
9. Tandem Labs New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
10. New method of selecting DNA for resequencing accelerates discovery of subtle DNA variations
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
(Date:12/1/2009)... SHANGHAI, Dec. 1 /PRNewswire-Asia/ -- Shanghai Ch...ma, a leading China-based Contract Research,Organi...e 2009 Deloitte,Technology Fast 50 China, ranking ...ompanies in China. The award is a testament to Che...rom 2006 to 2008. , The results of the 20...
(Date:12/1/2009)... Enterprise level storage is now availabl...without breaking the bank. , ... www.pacsdrive.com ), a medical imaging software ...atible cloud storage service. The PacsDrive servic...ders to securely archive medical imaging in compli...
(Date:12/1/2009)..., SAN DIEGO, Dec. 1 A...nounced today that it will present at the LD MICRO...p.m. (PST) at the Luxe Hotel in Los Angeles. Aethl...l present a corporate overview and will provide an... lead product, the Hemopurifier®, a first-in-...
(Date:12/1/2009)... FRANCISCO, Dec. 1 Mediz... announced today that in tests involving its propr... break "6 log" decontamination barriers, this time...laustridium difficile and Bacillis subtilis. These...xtremely potent sporicidal technology. "The implic...
Breaking Biology Technology:Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT 2Aethlon Medical to Present at LD MICRO Conference on December 3, 2009 2Medizone International Takes Aim at the Bioterrorism Countermeasures Arena 2
...MONTVALE, N.J., Feb. 28 Memory,Pharmaceuticals Co...report,its fourth quarter and full year 2007 finan...e U.S. financial markets open. Management will pro...sults during a conference call,on Thursday, March ...r interested parties may access the call as follow...
...TOKYO, Feb. 27 Kyowa Hakko Kogyo Co., Ltd. (Presi...rmaceutical, Inc. (New Jersey,United States), its ... 25,2008 (local time) a Not approvable letter from...stradefylline (KW-6002), its investigational drug,... not approvable letter FDA expressed concern if th...
..., A brief report in the February 28, 2008, New En...he New England Newborn Screening Program (NENSP) o...UMMS), indicates a declining incidence of a geneti...ration of a link between two independent populatio...chusetts has offered universal newborn screening t...
Other Biology Technology:Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008 2Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002) 2Data show a decline in cystic fibrosis since introduction of prenatal carrier screening 2
(Date:12/1/2009)...-run attacks by sharks can be solved with a new te... chomp they put on their victims, according to a U..., In a method analogous to analyzing human finge...ecisely comparing shark bites to the jaws and teet...director of the International Shark Attack File, w...
(Date:12/1/2009)...n ,abominable mystery, and it is a question which ...en did flowering plants evolve and how did they co...in Ecology Letters reveals the evolutionary trig...major competitive advantage over rival species, le...The study, by Dr Tim Brodribb and Dr Taylor Field...
(Date:11/30/2009)...view of the state of Antarctica,s climate and its ...shed this week (Tuesday 1 December) by the Scienti...eview - Antarctic Climate Change and the Environme...inent, identifies areas for future scientific rese...cy makers have about Antarctic melting, sea-level ...
Breaking Biology News(10 mins):New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3How did flowering plants evolve to dominate Earth? 2First comprehensive review of the state of Antarctica's climate 2The Cooper Institute Launches Nationwide Testing With Pearson VUE for Certified Personal Trainer 28CI CPT 29 Exam 53624 1The Cooper Institute Launches Nationwide Testing With Pearson VUE for Certified Personal Trainer 28CI CPT 29 Exam 53624 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 First Quarter Financial Results 53619 1Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 First Quarter Financial Results 53619 2Oramed Pharmaceuticals was Awarded a NIS 3 1 Million Grant From the Israeli Office of the Chief Scientist 13359 1Oramed Pharmaceuticals was Awarded a NIS 3 1 Million Grant From the Israeli Office of the Chief Scientist 13359 2
...i and Dartmouth College have reported the first pr... structures in yeast. , This research, published ... journal Nature Biotechnology, demonstrates that a...on) can be produced in glyco-engineered yeast cell...es of antibodies, their therapeutic potency can be...
...very, scientists have demonstrated that the progre... and symptoms are improved in mice that received c... March 22 issue of The Journal of Neuroscience , ... for metachromatic leukodystrophy, or MLD, a fatal...s usually begins early in life. In the disease, th...
...at occurred off the coast of El Salvador late last...urtles, according to test results released today b...r organizations. , Responding to requests from the...national Development (USAID)for assistance, WCS ve...the southern coast of El Salvador in January to he...
Other Biology News:GlycoFi announces the first production of antibodies with human glycosylation in yeast 2GlycoFi announces the first production of antibodies with human glycosylation in yeast 3Cell therapy slows progression of an inherited neurological disease; Improves motor skills in mice 2Red Tide causes sea turtle die-off in El Salvador 2
Sheep Anti-EBNA 3B Polyclonal Antibody, Unconjugated from Abcam
Goat Anti-Sarcosine Oxidase Polyclonal Antibody, HRP Conjugated from Abcam
Rabbit Anti-Human ZAP70, phospho (Tyr319) Monoclonal Antibody, Unconjugated, Clone E227 from Abcam
QCapture PRO from QImaging
Biology Products: